Servier in deal with CIMA in Alzheimer and Parkinson research

French independent drugmaker Servier has signed a collaboration agreement with the Center for Applied Medical Research (CIMA of the University of Navarra, Spain, to research two of the most prevalent neurodegenerative diseases in the world: Alzheimer’s and Parkinson’s diseases.

Through this alliance the pharmaceutical company supports CIMA in order to increase scientific knowledge on the treatment of these diseases and to carry out in-depth research into the causes and mechanisms which produce neurodegeneration. No financial details of the accord were disclosed.

The first agreement is to research the potential of a new target which has been identified in CIMA for the treatment of Alzheimer’s disease. Study of the target will allow for better understanding the disease, and the identification and development of potential new therapeutic agents.